Vion porfiromycin for head and neck cancer Phase III expanded trial planned -- IPO.

VION PORFIROMYCIN HEAD AND NECK CANCER EXPANDED PHASE III TRIAL planned with proceeds from the company's August 1995 initial public offering and a private placement of Class A preferred stock in May, Vion Pharmaceuticals states in a July 3 registration for resale by security holders. A Phase III trial is ongoing at Yale University, and the company is designing an expanded trial that will include additional sites. Porfiromycin has been designated an orphan drug by FDA.